Abbott Laboratories
ABT
$113.52
-$0.09-0.08%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 5.67% | 6.37% | 5.85% | 5.00% | 4.59% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.67% | 6.37% | 5.85% | 5.00% | 4.59% |
| Cost of Revenue | 3.50% | 5.48% | 3.94% | 3.24% | 4.05% |
| Gross Profit | 7.40% | 7.08% | 7.40% | 6.43% | 5.03% |
| SG&A Expenses | 5.48% | 15.04% | 15.41% | 16.10% | 17.41% |
| Depreciation & Amortization | -10.44% | -8.92% | -7.55% | -6.21% | -4.48% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.42% | 8.06% | 7.36% | 7.10% | 8.05% |
| Operating Income | 18.12% | -1.29% | -1.13% | -4.80% | -11.19% |
| Income Before Tax | 20.72% | 20.06% | 21.34% | 12.50% | 5.24% |
| Income Tax Expenses | 130.40% | -677.55% | -738.76% | -776.98% | -778.96% |
| Earnings from Continuing Operations | -51.32% | 142.36% | 151.56% | 139.82% | 134.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -51.32% | 142.36% | 151.56% | 139.82% | 134.18% |
| EBIT | 18.12% | -1.29% | -1.13% | -4.80% | -11.19% |
| EBITDA | 11.01% | -1.77% | -1.79% | -4.00% | -7.96% |
| EPS Basic | -51.46% | 142.33% | 151.80% | 140.76% | 135.09% |
| Normalized Basic EPS | 17.68% | 15.91% | 16.99% | 13.17% | 5.64% |
| EPS Diluted | -51.43% | 142.48% | 151.67% | 140.16% | 134.63% |
| Normalized Diluted EPS | 17.72% | 15.94% | 17.02% | 13.07% | 5.56% |
| Average Basic Shares Outstanding | 0.04% | 0.00% | -0.03% | -0.13% | -0.14% |
| Average Diluted Shares Outstanding | 0.00% | -0.04% | -0.08% | -0.06% | -0.05% |
| Dividend Per Share | 7.14% | 7.27% | 7.41% | 7.55% | 7.69% |
| Payout Ratio | 1.20% | -0.56% | -0.57% | -0.55% | -0.54% |